Phoenix chemical spill prompts 2 responses by crews: FD
Phoenix Fire crews were called to the scene of a chemical spill incident twice on May 26.
The first response happened at around 3:00 a.m.
One civilian was treated for possible inhalation injury, but not taken to the hospital.
PHOENIX - Phoenix Fire officials released more details surrounding a chemical spill incident on May 26 that prompted two responses.
What we know
Per a statement, crews were initially called to a commercial food warehouse in the area of 43rd Avenue and Buckeye Road at around 3:00 a.m.
"An employee was moving product when a 55-gallon drum of acid was punctured," read a portion of the statement. "The leaking drum was contained to a collection basin."
Fire officials said the warehouse was evacuated, and while one person was treated for a possible inhalation injury, that person was ultimately not taken to the hospital.
After crews confirmed the spill was contained and did not present a hazard to nearby areas, officials say the scene was turned over to a clean-up firm. However, crews were later called back to the scene when the clean-up firm made their way to the scene.
"A possible second reaction may have occurred when the acid combined with residual chemicals in the containment basin," read a portion of the statement. "Hazmat crews made a second entry and found that the spill was still contained and not reacting. The environment inside and outside was metered and found to be non-hazardous."
Officials say crews who made their way inside the building went through a decontamination procedure as a safety precaution. No firefighters were injured.
What's next
Officials say a fire prevention unit will remain on scene to help with cleanup efforts.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Adia Nutrition Inc. Supports Heroes and Their Families with TRICARE In-Network Application, Advancing Regenerative Care Through Adia Med
Winter Park, Florida--(Newsfile Corp. - July 23, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a publicly traded leader in regenerative medicine and personalized wellness solutions, is thrilled to announce that its medical subsidiary, Adia Med, has officially filed to become an in-network provider with TRICARE, the healthcare program serving approximately 9.5 million active-duty service members, retirees, National Guard and Reserve members, and their families worldwide. This step, paired with Adia Med's anticipated approval as a United Healthcare provider by August 1, 2025, positions the company to transform healthcare access for millions. Adia Med expects to secure TRICARE in-network provider status by August 31, 2025, tapping into a program that paid out $50.6 billion for medical treatments in FY2019 to support its beneficiaries. Evaluation of the TRICARE Program: Fiscal Year 2019 Report to Congress. To view an enhanced version of this graphic, please visit: This strategic filing positions Adia Med to serve TRICARE's extensive network of beneficiaries, including military personnel and their families, by offering innovative regenerative treatments such as Umbilical Cord Blood Stem Cell (UCB-SC) therapies, Autologous Hematopoietic Stem Cell Transplantation (AHSCT), and Therapeutic Plasma Exchange (TPE). These therapies, provided at Adia Med's Winter Park clinic and planned satellite locations, target conditions like Multiple Sclerosis, joint pain, torn tendons, and other orthopedic and wellness needs, aligning with Adia Nutrition's mission to revolutionize healthcare accessibility. "We're fired up to support the 9.5 million TRICARE beneficiaries, including our nation's military heroes and their families, by bringing our regenerative therapies into their reach," said Larry Powalisz, CEO of Adia Nutrition Inc. "With TRICARE's massive $50.6 billion investment in medical care, our filing to join their network, alongside our imminent United Healthcare approval, will make advanced treatments more accessible and affordable, driving transformative health outcomes and fueling Adia Med's growth." The TRICARE filing complements Adia Med's recent progress with United Healthcare, where the company has already begun submitting its first patient insurance claims, signaling near-final integration. By securing in-network status with both TRICARE and United Healthcare, Adia Med will join an elite group of providers meeting rigorous standards for clinical excellence, compliance, and patient care. These partnerships will enable insurance reimbursement for Adia Med, enhancing affordability and accessibility for patients seeking innovative treatments. For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
17 minutes ago
- Yahoo
Analysis-Five years after COVID, pharma shares languish in US policy limbo
By Danilo Masoni MILAN (Reuters) -Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies since Donald Trump returned to the White House. Pharma companies' earnings outlook is being obscured by concerns over revived "most-favored-nation" drug pricing rules in the lucrative U.S. market and potential 200% tariffs on pharma imports into the U.S. Money flooded into drugmakers' shares during the COVID-19 pandemic but more recently there has been an exodus as investors shifted into Big Tech, leaving the sector cheap but unloved. At 15.9 times forward earnings, healthcare trades 11% below its long-term average and 20% below global equities, its steepest discount in 16 years, just above a record discount in 2009, based on LSEG Datastream data. "We've moved from cautious optimism to cautious pessimism," said Stephanie Aliaga, global market strategist at J.P. Morgan Asset Management in New York. "Valuations have gotten even cheaper, but for a reason," she added, referring to intensifying U.S. policy risks. But some investors are starting to look past the Washington policy fog and at long-term positive drivers, such as aging populations, RNA-based therapeutics, and breakthroughs in weight-loss and diabetes drugs. 'ARMAGEDDON SCENARIO' Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, drawn by strong cash-flow yields and the prospect of U.S. rate cuts boosting this rate-sensitive sector. Interest rate cuts typically support healthcare by lowering R&D funding costs and boosting the value of future cash flows. "These are quality companies with good growth and defensive features being priced as if we're heading into an 'Armageddon scenario', which I believe is unlikely," he said. UK-based M&G Investments has also been selectively adding to healthcare, according to its latest allocation report. Healthcare funds have seen net inflows since 2024, more than reversing the outflows from late 2022 through 2023, fund tracker EPFR data shows. Although year-to-date, inflows total $7.2 billion, down 41% from last year. Innovation is accelerating, pipelines are maturing and M&A is showing signs of picking up - yet stock prices are unmoved. Whether that represents a buying opportunity or a value trap hinges on how and when the policy uncertainty clears, investors said. CATALYST NEEDED Historically, healthcare has traded at a modest premium to world stocks, thanks to its defensive profile and steady earnings. But that narrative has unravelled under political pressure from Washington and investors' love of Big Tech. Over the past three years, U.S. healthcare has underperformed the S&P 500 by more than 60 percentage points, making it the worst sectoral performer on Wall Street. Its valuation has deepened to a near-record 27% discount, from parity to the S&P in 2023. "Markets don't like uncertainty, and that shows up in valuations," said Eddie Yoon, healthcare sector leader and portfolio manager at Fidelity Investments in Boston. "Being cheap isn't necessarily a reason to buy. You need a catalyst." For now, that catalyst is elusive. The policy uncertainty makes it difficult to forecast future earnings, he said, though he hopes for more clarity by year-end - potentially also paving the way for more M&A in the industry. Talks with the Trump administration have yet to clarify how and when drug prices will fall, executives from Eli Lilly and Merck said at a May industry conference. Yoon, who has typically been underweight Big Pharma due to patent expiry risks, notes smaller, innovative firms are becoming profitable. "We're seeing companies go from unprofitable to very profitable," he said, citing Alnylam and Penumbra as examples he owns. "Historically, that's been a very good time to own healthcare stocks." LFG+ZEST's Conca, who favours U.S. names like Abbott, Edwards Lifesciences, and AbbVie, along with Sanofi and Recordati in Europe, said interest rate cuts could be a major catalyst. OUT OF THE WOODS? In Europe, healthcare is even cheaper than U.S. pharma, trading at 14.3 times forward earnings. A 55% drop in shares of Novo Nordisk in the last year, related in part to concerns over competition in obesity drugs, along with tariff-driven production shifts to the U.S., has weighed on valuations. "The sector will adapt," wrote Arnaud Cadart, healthcare analyst at France's CIC Market Solutions. But that will come "at the cost of rebalancing its revenues and probably transforming its organisations." AstraZeneca, for example, has unveiled a $50 billion U.S. investment. For now, the sector remains in limbo: cheap, but lacking enough visibility to trigger a broad re-rating. "Healthcare has endured a lot of pain," said J.P. Morgan's Aliaga. "We're not sure if that pain is done, but the worst is likely over, given how extreme the exodus has been."


Associated Press
20 minutes ago
- Associated Press
Oliva Therapeutics Announces Availability of Thyquidity® (Levothyroxine Sodium Oral Solution)
RIDGEWOOD, N.J.--(BUSINESS WIRE)--Jul 23, 2025-- Oliva Therapeutics, a US-based healthcare company focused on product commercialization, sales, marketing, distribution, and promotion, announced today the relaunch and immediate availability of Thyquidity® (Levothyroxine Sodium Oral Solution). This press release features multimedia. View the full release here: 'We are grateful for the patience shown by the existing Thyquidity® patient base as we worked tirelessly with our manufacturing partner to deliver new supply,' said Michael Turnamian, COO of Oliva Therapeutics. 'Thyquidity® offers a flexible option with several years of proven reliability.' In partnership with Jerome Stevens Pharmaceuticals, Inc., a US-based prescription pharmaceutical manufacturer and packager, the launch of Thyquidity® represents the first branded product launch for Oliva Therapeutics and expands upon a joint endocrine-focused portfolio and pipeline. 'The relaunch of Thyquidity® represents the next step in our family vision as a leader in the thyroid therapeutic class,' said Daniel Akeson, Director of Jerome Stevens Pharmaceuticals and CEO of Oliva Therapeutics, LLC. 'We look forward to ensuring reliable supply and executing our near-term endocrine pipeline.' Oliva Therapeutics has established a monitored email address for customers and patients to support product locating and ordering, [email protected], as well as a regularly updated information page at Product Numbers & Ordering Information: Cardinal Health – 6043475 Cencora – 10301755 McKesson – 3046661 View source version on Media:[email protected] KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY INDUSTRY KEYWORD: BIOTECHNOLOGY MANUFACTURING HEALTH PHARMACEUTICAL CHEMICALS/PLASTICS SOURCE: Oliva Therapeutics Copyright Business Wire 2025. PUB: 07/23/2025 09:22 AM/DISC: 07/23/2025 09:22 AM